STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Rhea-AI Summary
PureTech Health plc announces the completed acquisition of Karuna Therapeutics, Inc. by Bristol Myers Squibb for approximately $14 billion. PureTech to receive $293 million gross proceeds from its equity position in Karuna. KarXT, a potential first-in-class treatment for schizophrenia, has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. Bristol Myers Squibb expects the transaction to be dilutive to its non-GAAP diluted earnings per share by approximately $0.30 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
acquisition
-
News
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Rhea-AI Summary
Bristol Myers Squibb (BMY) successfully completes the acquisition of Karuna Therapeutics, adding KarXT to its neuroscience portfolio. KarXT, an antipsychotic, has a novel mechanism of action with potential for multiple indications. The acquisition is expected to be dilutive to BMY's non-GAAP diluted earnings per share by approximately $0.30 in 2024 due to financing costs. The transaction includes a one-time, non-deductible Acquired In-Process Research and Development charge of approximately $12 billion. BMY plans to offset operational expenses through disciplined resource allocation and cost efficiencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
acquisition
-
News
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio announced positive FDA committee vote for Abecma in multiple myeloma treatment. Abecma's favorable benefit/risk profile was recognized based on KarMMa-3 study results. FDA review ongoing with no set action date yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
News
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Rhea-AI Summary
Bristol Myers Squibb's Breyanzi, a CD19-directed CAR T cell therapy, receives FDA accelerated approval for treating adult patients with relapsed or refractory CLL or SLL. The therapy offers a one-time infusion with 20% of patients achieving a complete response in a pivotal trial. Breyanzi is now FDA approved for large B-cell lymphoma and CLL or SLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
fda approval
-
News
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
Rhea-AI Summary
Bristol Myers Squibb (BMY) will release its first-quarter 2024 financial results on April 25, 2024. Investors and the public can join the conference call to hear executives discuss the results. The call will be available via webcast or phone, with materials provided beforehand. A replay will also be accessible for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
conferences earnings
-
News
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Rhea-AI Summary
Bristol Myers Squibb's Opdivo, in combination with cisplatin and gemcitabine, receives FDA approval for first-line treatment of urothelial carcinoma, showing significant improvements in overall survival and progression-free survival compared to standard treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
fda approval
News
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Bristol Myers Squibb (BMY) to participate in two investor conferences in March 2024. Samit Hirawat, M.D., to speak at Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
News
Bristol Myers Squibb Announces Dividend
Rhea-AI Summary
Bristol Myers Squibb (BMY) declares quarterly dividends for common and preferred stockholders, with $0.60 per share for common stock and $0.50 per share for convertible preferred stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
dividends
-
News
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
Rhea-AI Summary
Bristol Myers Squibb announces positive results from the Phase 3 DAYBREAK trial, showcasing Zeposia's long-term efficacy and safety in patients with relapsing forms of multiple sclerosis. The study reveals a low annualized relapse rate, absence of confirmed disability progression, and consistent safety profile over nearly 10 years. These findings reinforce Zeposia's role as a significant treatment option for MS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
News
Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors
Rhea-AI Summary
Tapestry, Inc. (TPR) appoints Kevin Hourican and David Elkins to its Board of Directors, bringing significant strategic and financial expertise to the company. Hourican, President and CEO of Sysco Corporation, and Elkins, EVP and CFO of Bristol Myers Squibb, join as independent directors, enhancing Tapestry's global growth and transformation initiatives. The additions aim to drive innovation, shareholder returns, and sustainable growth for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
management
Stock BMY logo
Bristol-Myers Squibb Co.

Nasdaq:BMY

BMY Rankings

#129 Ranked by Market Cap
#4058 Ranked by Stock Gains
#576 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.